drugset / Trial / NCT05018676
ARX788 in Breast Cancer With Low Expression of HER2
NaSingle-groupOpen-labelTreatment
Summary
A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2022-12-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANVATABART OPADOTIN | Other / unclassified | 1.5 mg/kg | Intravenous |